Headline: "Hedge funds bleed as AbbVie reconsiders Shire bid".
Some of them levered up their positions and are getting margin calls. Don't you feel bad for them...NOT.
That's just it, Lucentis and Fovista are combined in a single syringe, no additional injections are necessary. Patients won't even know the difference when being injected. If the Lucentis+Fovista combo works better than Lucentis alone, that will become the new standard of care, that will be what the additional use of squalamine will have to improve. OPHT is more than one year into the Fovista Phase 3.
The goalposts are likely to move during the study. Even if squalamine meets the proposed FDA endpoints, the standard of care will probably become Lucentis+Fovista. Then eye doctors will want to know how much squalamine improves that combo before they prescribe it. The world doesn't stand still.
OK, went from 5% to 30% cash in ten minutes, talked myself into it. I'll sleep better tonight. Let's hear it for cheap online trading!
Shades of 2008... I just saw the DJI drop about 100 points in two minutes. I'm heavy into REIT's and even preferred stocks for dividends right now, they have been holding up quite well. But I'm getting antsy, probably won'[t lose much by selling now and buying back later.
Can reduced sales of bonders be far behind? The switch to copper has pretty much played out. I wouldn't be surprised to see a nasty guide down for the next quarter when earnings are reported.
It's 4forallMannkind now. All the Manniacs who claimed True Religion, it looks like you were worshipping at the wrong altar. You can still sell and get a good pair of jeans at Gap.
-- "If BEACON data is as good as Ph 2"
The Phase 2 data was single arm. The Phase 3 was started on the basis of a data-mined 16 patient subset. The one thing you can say that was exceptional about Phase 2 was the side effect profile. The main thing Phase 3 has going for it is that statistical OS/HR non-inferiority is probably all that is needed for NKTR to pursue approval. The money NKTR stands to get from sales or partnership, which is what really matters and will drive the stock price, directly depends on the superiority/inferiority trend.
Whether or not you like the company's prospects, it should be good for a 10-20% run into the data release in December. I'd be shocked if BLUE didn't trade into the $40's before then. Biotech stock advances into important data releases have been one of the surest trades in the market the past few years.
Probably going nowhere if it gets approved by EMA. Think of approval as a hunting license. You still need to go out and shoot the deer. To sell anything more than a miniscule amount, it needs to be written into the standard of care. Given the mediocre results and the unlikeliness of FDA approval, vosaroxin will be lucky to end up listed as a possible drug of last resort. The world is littered with approved drugs with little or no sales.
What's nice about it is that that the Extensions service works on cellular, 3G/4G and/or wifi. I have Vonage and travel to Canada every now and then. I get hit with ridiculous phone charges if I take my cell phone there. Next time I go, I'm going to put the phone in airplane mode and set extensions to wifi only. If it works in a public wifi area, then I have a way of making and receiving calls there. And if it works there, it might work overseas as well. Anyone have experience with this?
What gets AF and others upset is a profiteering loophole attempted by companies like QCOR, RTRX and CPRX. Start with an inexpensive drug that has been off-patent for years if not decades, but happens to be the only effective treatment for an uncommon disease. Move it to closed distribution (RTRX) or exploit orphan drug laws (CPRX) to prevent others from developing and marketing competing generic versions. Start charging patients tens of thousands of dollars per year for the drug. This is the polar opposite of innovative drug research and development.
Shkreli also has a shady background in both his professional stock trading and personal life, which has been documented many places including recent SA articles. The exploitive RTRX moves with Chenodal and Thiola seem perfectly in character with Shkreli's past.
It got so bad even the non-independent directors wanted him out. Guess he'll be filing for unemployment now. In New York, the maximum unemployment benefit is $405/week for 26 weeks. See you at the retraining center, Marty!
Auditors have a "going concern" statement in the 10-Q's for the past several quarters. No financing = Involuntary BK.
Good news for CPRX, Firdapse Phase 3 was successful. But search for "Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug".
And we all know what Shkreli is doing to the employee while he is behind there.
That article documents other slimeball activity... hacking employee social media accounts and lying to a police officer.